Close Menu

NEW YORK – Veracyte said after the market closed Tuesday afternoon that it has priced a public offering of 6 million shares of its common stock at $30 per share. It expects gross proceeds of around $180 million.

Veracyte will use the net proceeds from the offering for working capital and other general corporate purposes. The firm may also use part of the proceeds to acquire or invest in complementary businesses, technologies, or other assets.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

Time magazine looks into how liquid biopsies are changing cancer care.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.